| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.03▲ | 2.01▲ | 2.01▲ | 2.02▲ | 2.19▼ |
| MA10 | 2.02▲ | 2.00▲ | 1.99▲ | 2.11▼ | 2.16▼ |
| MA20 | 2.01▲ | 1.99▲ | 2.00▲ | 2.19▼ | 2.50▼ |
| MA50 | 1.99▲ | 2.01▲ | 2.07▼ | 2.17▼ | 3.15▼ |
| MA100 | 1.99▲ | 2.09▼ | 2.15▼ | 2.54▼ | 3.01▼ |
| MA200 | 2.00▲ | 2.16▼ | 2.21▼ | 2.98▼ | 2.40▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.007▲ | 0.010▲ | -0.028▼ | 0.003▲ |
| RSI | 66.003▲ | 59.631▲ | 53.215▲ | 40.269▼ | 38.646▼ |
| STOCH | 89.167▲ | 87.456▲ | 74.797 | 15.734▼ | 46.815 |
| WILL %R | 0.000▲ | 0.000▲ | -30.556 | -69.767 | -80.303▼ |
| CCI | 158.865▲ | 126.172▲ | 87.956 | -117.736▼ | -118.370▼ |
|
Thursday, November 20, 2025 12:39 PM
Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report ...
|
|
Friday, November 07, 2025 12:38 AM
Cardiff Oncology, Inc. ( (CRDF)) has released its Q3 earnings. Here is a breakdown of the information Cardiff Oncology, Inc. presented to its investors. Cardiff Oncology, Inc. is a clinical-stage ...
|
|
Wednesday, October 22, 2025 05:46 AM
Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 21/11/25 | 1.96 | 2.04 | 1.90 | 2.03 | 1,234,500 |
| 20/11/25 | 2.03 | 2.10 | 1.95 | 1.96 | 850,800 |
| 19/11/25 | 2.02 | 2.06 | 1.96 | 2.00 | 826,800 |
| 18/11/25 | 2.07 | 2.0987 | 1.99 | 2.04 | 1,045,150 |
| 17/11/25 | 2.10 | 2.165 | 2.035 | 2.06 | 859,446 |
| 14/11/25 | 2.14 | 2.19 | 2.09 | 2.13 | 814,400 |
| 13/11/25 | 2.24 | 2.25 | 2.14 | 2.15 | 916,237 |
| 12/11/25 | 2.30 | 2.31 | 2.22 | 2.24 | 327,955 |
| 11/11/25 | 2.21 | 2.31 | 2.21 | 2.29 | 345,574 |
| 10/11/25 | 2.21 | 2.28 | 2.17 | 2.23 | 646,300 |
|
|
||||
|
|
||||
|
|